湖北济川药业拟回购注销17.18万股限制性股票 涉及离职及考核不达标激励对象

Core Viewpoint - Hubei Jichuan Pharmaceutical Co., Ltd. plans to repurchase and cancel 171,800 restricted stocks from its 2022 incentive plan due to the departure of some incentive targets and unsatisfactory performance evaluations [1][2][6] Repurchase Background and Basis - The repurchase is based on the 2022 incentive plan approved on August 22, 2022, aimed at binding the interests of the core team to promote long-term development [2] - According to the plan, if an incentive target leaves or fails to meet performance standards, their unvested restricted stocks will not be released and will be repurchased at the grant price plus interest [2] Specifics of the Repurchase - The total number of restricted stocks to be repurchased is 171,800, all from the initial grant of the 2022 incentive plan [3] Repurchase Price and Funding Source - The repurchase price is set at 16.00 yuan per share, the same as the grant price, with no adjustments due to unvested status [4] - The funding for the repurchase will come entirely from the company's own funds, ensuring no significant impact on daily cash flow [4] Subsequent Arrangements - The company has opened a dedicated securities account for the repurchase and submitted the necessary applications for stock cancellation and registration [5] Compliance with Procedures - Legal opinions confirm that the repurchase has followed all necessary approval and authorization procedures, complying with relevant laws and the incentive plan [6] Market Impact - The repurchase of non-compliant shares is a common practice to maintain the integrity of the incentive plan and protect the interests of the company and its shareholders [7] - The number of shares involved is small relative to the total share capital, and the action is expected to optimize the incentive mechanism and focus on stabilizing the core team [8]